AMO, Pharma

AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 in Treatment of Myotonic Dystrophy

Published on 08/07/2025 at 18:03 | prnewswire.co.uk

AMO Pharma Limited United Kingdom

en | boerse | 67997525 |